A Phase 3, Randomised, Double-blind, Parallel-group, 76-week, Efficacy and Safety Study of BI 456906 Administered Subcutaneously Compared With Placebo in Participants With Overweight or Obesity and Type 2 Diabetes Mellitus
Latest Information Update: 05 Mar 2025
At a glance
- Drugs Survodutide (Primary)
- Indications Obesity; Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Acronyms SYNCHRONIZE-2
- Sponsors Boehringer Ingelheim
Most Recent Events
- 10 Feb 2025 Planned End Date changed from 16 Jan 2026 to 3 Apr 2026.
- 10 Feb 2025 Planned primary completion date changed from 19 Dec 2025 to 12 Dec 2025.
- 25 Jun 2024 Status changed from recruiting to active, no longer recruiting.